1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Lauber, T. Roesch, P. Marx, U.C. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking UK J.Mol.Biol. JMOBAK 0070 0022-2836 328 205 10.1016/S0022-2836(03)00245-6 12684009 Homologous Proteins with Different Folds: The Three-Dimensional Structures of Domains 1 and 6 of the Multiple Kazal-Type Inhibitor Lekti 2003 10.2210/pdb1hdl/pdb pdb_00001hdl 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 DISULFIDE BRIDGES BETWEEN CYS 8 AND CYS 44, AND BETWEEN CYS 21 AND CYS 41 6491.618 SERINE PROTEINASE INHIBITOR LEKTI LEKTI DOMAIN ONE 1 man polymer HF6478 no no KNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFINKCATCKMILEKEAKSQ KNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFINKCATCKMILEKEAKSQ A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN I.E. VAGINAL EPITHELIUM sample 9606 HOMO SAPIENS CYTOPLASM 562 ESCHERICHIA COLI ORIGAMI (DE3) PET32A pdbx_database_status pdbx_nmr_software database_2 pdbx_database_status repository Initial release Version format compliance Version format compliance Data collection Other Database references Other 1 0 2001-11-15 1 1 2011-05-08 1 2 2011-07-13 1 3 2020-01-15 1 4 2023-06-14 _pdbx_database_status.status_code_cs _pdbx_database_status.status_code_mr _pdbx_nmr_software.name _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data LEKTI DOMAIN SIX (HF7665) HELIX DETERMINATION METHOD: AUTHOR PROVIDED. SHEET DETERMINATION METHOD: AUTHOR PROVIDED. PDBE Y PDBE 2000-11-16 REL REL REL REL THE SEQUENCE FOR RESIDUES A 2 TO A 5 ARE IN CONFLICT WITH THE SWISS-PROT SEQUENCE DATABASE AND HAVE BEEN DESCRIBED BY MAEGERT H.-J.,J.BIOL.CHEM. (1999) THE STRUCTURE WAS DETERMINED USING STANDARD NMR TECHNIQUES ON 15N-LABELED AND UNLABELED HF6478 LOWEST ENERGY 60 21 2D-TOCSY 2D-NOESY 2D-COSY 1H 15N-HSQC HNHA 3D-1H 15N-TOCSY-HSQC 3D-1H 15N-NOESY-HSQC 3D-1H 15N/1H 15N-HMQC-NOESY-HSQC 4.5 pH 1 atm 298 K simulated annealing 3 BRUNGER refinement X-PLOR 3.851 structure solution NDEE structure solution NMRView 4.1.0 structure solution X-PLOR 3.851 600 Bruker DRX LYS 1 n 1 LYS 1 A ASN 2 n 2 ASN 2 A GLU 3 n 3 GLU 3 A ASP 4 n 4 ASP 4 A GLN 5 n 5 GLN 5 A GLU 6 n 6 GLU 6 A MET 7 n 7 MET 7 A CYS 8 n 8 CYS 8 A HIS 9 n 9 HIS 9 A GLU 10 n 10 GLU 10 A PHE 11 n 11 PHE 11 A GLN 12 n 12 GLN 12 A ALA 13 n 13 ALA 13 A PHE 14 n 14 PHE 14 A MET 15 n 15 MET 15 A LYS 16 n 16 LYS 16 A ASN 17 n 17 ASN 17 A GLY 18 n 18 GLY 18 A LYS 19 n 19 LYS 19 A LEU 20 n 20 LEU 20 A PHE 21 n 21 PHE 21 A CYS 22 n 22 CYS 22 A PRO 23 n 23 PRO 23 A GLN 24 n 24 GLN 24 A ASP 25 n 25 ASP 25 A LYS 26 n 26 LYS 26 A LYS 27 n 27 LYS 27 A PHE 28 n 28 PHE 28 A PHE 29 n 29 PHE 29 A GLN 30 n 30 GLN 30 A SER 31 n 31 SER 31 A LEU 32 n 32 LEU 32 A ASP 33 n 33 ASP 33 A GLY 34 n 34 GLY 34 A ILE 35 n 35 ILE 35 A MET 36 n 36 MET 36 A PHE 37 n 37 PHE 37 A ILE 38 n 38 ILE 38 A ASN 39 n 39 ASN 39 A LYS 40 n 40 LYS 40 A CYS 41 n 41 CYS 41 A ALA 42 n 42 ALA 42 A THR 43 n 43 THR 43 A CYS 44 n 44 CYS 44 A LYS 45 n 45 LYS 45 A MET 46 n 46 MET 46 A ILE 47 n 47 ILE 47 A LEU 48 n 48 LEU 48 A GLU 49 n 49 GLU 49 A LYS 50 n 50 LYS 50 A GLU 51 n 51 GLU 51 A ALA 52 n 52 ALA 52 A LYS 53 n 53 LYS 53 A SER 54 n 54 SER 54 A GLN 55 n 55 GLN 55 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N LYS 16 A N LYS 16 A O LYS 19 A O LYS 19 1 A A H O LYS LYS 16 19 1.54 1 A A O H PHE PHE 11 14 1.55 1 A A O H LYS CYS 40 44 1.56 1 A A O H LYS PHE 26 29 1.59 2 A A H O LYS LYS 16 19 1.54 2 A A O H PHE PHE 11 14 1.54 2 A A O H LYS CYS 40 44 1.55 3 A A H O LYS LYS 16 19 1.53 3 A A O H PHE PHE 11 14 1.55 3 A A O H LYS CYS 40 44 1.57 3 A A O H SER ILE 31 35 1.58 4 A A O H PHE PHE 11 14 1.55 4 A A O H PHE SER 28 31 1.58 4 A A H O LYS LYS 16 19 1.58 5 A A O H LYS CYS 40 44 1.54 5 A A O H PHE PHE 11 14 1.55 5 A A H O LYS LYS 16 19 1.57 6 A A O H PHE SER 28 31 1.57 6 A A O H PHE PHE 11 14 1.58 6 A A O H LYS CYS 40 44 1.58 7 A A H O LYS LYS 16 19 1.51 7 A A O H PHE PHE 11 14 1.56 7 A A O H PHE CYS 37 41 1.59 8 A A H O LYS LYS 16 19 1.54 8 A A O H PHE PHE 11 14 1.55 8 A A O H LYS CYS 40 44 1.56 8 A A O H PHE SER 28 31 1.58 9 A A O H LYS CYS 40 44 1.54 9 A A H O LYS LYS 16 19 1.55 9 A A O H PHE PHE 11 14 1.56 9 A A O H GLN MET 5 7 1.57 10 A A O H PHE PHE 11 14 1.57 10 A A O H PHE CYS 37 41 1.58 11 A A O H LYS CYS 40 44 1.54 11 A A H O LYS LYS 16 19 1.56 11 A A O H PHE PHE 11 14 1.56 11 A A O H PHE CYS 37 41 1.56 12 A A O H PHE PHE 11 14 1.56 12 A A O H LYS CYS 40 44 1.59 13 A A H O LYS LYS 16 19 1.52 13 A A O H PHE PHE 11 14 1.55 14 A A H O LYS LYS 16 19 1.55 14 A A O H PHE PHE 11 14 1.56 14 A A O H LYS PHE 26 29 1.56 14 A A O H SER ILE 31 35 1.59 15 A A O H LYS CYS 40 44 1.53 15 A A O H PHE PHE 11 14 1.54 15 A A H O LYS LYS 16 19 1.58 15 A A O H LYS PHE 26 29 1.60 16 A A O H PHE PHE 11 14 1.55 17 A A O H LYS CYS 40 44 1.56 17 A A O H PHE PHE 11 14 1.57 17 A A H O LYS LYS 16 19 1.57 18 A A O H PHE PHE 11 14 1.57 18 A A H O LYS LYS 16 19 1.59 19 A A O H PHE PHE 11 14 1.56 19 A A O H LYS CYS 40 44 1.56 19 A A O H PHE CYS 37 41 1.58 20 A A O H PHE PHE 11 14 1.55 20 A A O H SER ILE 31 35 1.56 20 A A O H GLN MET 5 7 1.57 20 A A O H PHE SER 28 31 1.58 21 A A O H PHE PHE 11 14 1.56 21 A A O H SER ILE 31 35 1.58 1 A PRO 23 -63.82 84.45 1 A GLN 24 -121.70 -83.94 1 A CYS 41 -65.26 -71.61 2 A MET 7 -41.60 165.40 2 A PRO 23 -65.30 79.09 2 A GLN 24 -122.19 -112.96 3 A GLN 5 69.86 -71.64 3 A GLU 6 -69.04 59.73 3 A PRO 23 -61.99 83.12 3 A GLN 24 -126.56 -77.11 3 A CYS 41 -54.33 -71.80 4 A MET 7 58.81 -142.99 4 A PRO 23 -62.35 73.86 4 A ASP 25 -165.03 64.67 4 A CYS 41 -54.66 -72.44 5 A ASP 4 -152.61 84.90 5 A PRO 23 -62.43 82.69 5 A GLN 24 -125.63 -76.48 5 A CYS 41 -60.61 -73.48 6 A ASP 4 46.20 24.78 6 A GLU 6 -144.19 25.62 6 A PRO 23 -62.05 83.11 6 A GLN 24 -112.38 -79.61 7 A HIS 9 -135.80 -39.39 7 A PHE 21 -103.48 73.58 7 A PRO 23 -61.56 82.54 7 A GLN 24 -126.02 -78.35 7 A CYS 41 -53.86 -75.61 8 A PHE 21 -101.73 64.16 8 A PRO 23 -65.19 84.27 8 A ASP 25 -179.97 55.04 9 A GLN 5 57.84 -85.01 9 A GLU 6 -68.53 60.70 9 A MET 7 -39.56 -30.55 9 A HIS 9 -132.14 -44.86 9 A PRO 23 -61.58 82.74 9 A GLN 24 -120.77 -86.13 10 A GLN 5 75.44 -47.58 10 A GLU 6 -38.79 -30.05 10 A CYS 8 -45.29 -78.73 10 A HIS 9 47.93 24.67 10 A LYS 16 -105.31 77.64 10 A PRO 23 -61.12 82.06 10 A GLN 24 -113.45 -78.31 10 A CYS 41 -42.61 -73.46 11 A GLU 6 -141.72 44.67 11 A PRO 23 -62.01 73.79 11 A ASP 25 -171.81 61.00 11 A CYS 41 -47.04 -72.25 12 A ASP 4 -110.02 55.97 12 A GLN 5 -114.77 64.77 12 A PHE 21 -101.30 74.74 12 A PRO 23 -65.46 75.75 12 A GLN 24 -119.98 -113.29 13 A MET 7 59.19 -160.70 13 A PHE 21 -103.49 69.56 13 A PRO 23 -62.41 83.98 13 A GLN 24 -125.97 -78.72 13 A PHE 29 -49.76 -19.49 13 A CYS 41 -50.62 -74.57 14 A ASP 4 -119.41 -102.66 14 A GLN 5 176.62 -34.62 14 A PRO 23 -63.19 72.70 14 A GLN 24 -105.38 -91.18 15 A GLU 6 -156.83 33.53 15 A PRO 23 -62.28 82.00 15 A GLN 24 -115.54 -91.26 15 A LYS 27 -39.83 -27.54 16 A PRO 23 -63.03 75.29 16 A GLN 24 -120.22 -85.71 16 A CYS 41 -58.63 -74.17 17 A PRO 23 -59.20 78.17 17 A GLN 24 -105.94 -89.29 17 A CYS 41 -41.09 -72.70 18 A GLN 5 -177.14 -32.58 18 A HIS 9 -162.49 -36.67 18 A PRO 23 -66.08 82.75 18 A GLN 24 -128.96 -110.44 19 A HIS 9 -127.35 -50.70 19 A PRO 23 -62.61 83.86 19 A GLN 24 -124.29 -78.76 19 A CYS 41 -50.22 -75.34 20 A GLN 5 58.82 -85.26 20 A GLU 6 -68.76 60.61 20 A PHE 21 -107.01 75.72 20 A PRO 23 -61.83 70.36 20 A GLN 24 -106.91 -74.02 21 A GLN 5 63.33 -70.52 21 A MET 7 56.16 104.99 21 A PRO 23 -62.38 82.11 LEKTI domain one 1 N N A GLN 12 A GLN 12 HELX_P A PHE 14 A PHE 14 1 1 3 A LYS 26 A LYS 26 HELX_P A GLN 30 A GLN 30 1 2 5 A LEU 32 A LEU 32 HELX_P A ALA 52 A ALA 52 1 3 21 disulf 2.020 A CYS 8 A SG CYS 8 1_555 A CYS 44 A SG CYS 44 1_555 disulf 2.020 A CYS 22 A SG CYS 22 1_555 A CYS 41 A SG CYS 41 1_555 PUTATIVE SERINE PROTEINASE INHIBITOR PUTATIVE SERINE PROTEINASE INHIBITOR ISK5_HUMAN UNP 1 Q9NQ38 23 77 1HDL 1 55 Q9NQ38 A 1 1 55 1 ASP variant ASN 2 1HDL A Q9NQ38 UNP 24 2 1 SER variant GLU 3 1HDL A Q9NQ38 UNP 25 3 1 LEU variant ASP 4 1HDL A Q9NQ38 UNP 26 4 1 SER variant GLN 5 1HDL A Q9NQ38 UNP 27 5 2 anti-parallel A MET 15 A MET 15 A LYS 16 A LYS 16 A LYS 19 A LYS 19 A LEU 20 A LEU 20 1 P 1